IMCR Stock Overview
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Immunocore Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$58.00 |
| 52 Week High | US$76.98 |
| 52 Week Low | US$42.21 |
| Beta | 0.89 |
| 1 Month Change | -5.94% |
| 3 Month Change | -17.12% |
| 1 Year Change | -1.34% |
| 3 Year Change | 45.00% |
| 5 Year Change | n/a |
| Change since IPO | 34.26% |
Recent News & Updates
Recent updates
Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?
Apr 05
Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money
Jan 22Immunocore Holdings: Vulnerable To Profit Taking After Big Rally
Jan 21Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%
Dec 18Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S
May 08Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically
Nov 16Immunocore: Attractive Commercial-Stage Biopharma
Oct 05Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)
Aug 12Immunocore GAAP EPS of -$0.17, revenue of $38.92M
Aug 10Immunocore to raise $140M in private placement financing
Jul 18Analysts Are Updating Their Immunocore Holdings plc (NASDAQ:IMCR) Estimates After Its Second-Quarter Results
Aug 15Industry Analysts Just Upgraded Their Immunocore Holdings plc (NASDAQ:IMCR) Revenue Forecasts By 12%
May 20Shareholder Returns
| IMCR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.0% | 1.0% | 1.2% |
| 1Y | -1.3% | 0.7% | 24.9% |
Return vs Industry: IMCR underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: IMCR underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| IMCR volatility | |
|---|---|
| IMCR Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IMCR's share price has been volatile over the past 3 months.
Volatility Over Time: IMCR's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 497 | Bahija Jallal | www.immunocore.com |
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Immunocore Holdings plc Fundamentals Summary
| IMCR fundamental statistics | |
|---|---|
| Market cap | US$2.93b |
| Earnings (TTM) | -US$55.29m |
| Revenue (TTM) | US$249.43m |
11.7x
P/S Ratio-52.9x
P/E RatioIs IMCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMCR income statement (TTM) | |
|---|---|
| Revenue | US$249.43m |
| Cost of Revenue | US$164.58m |
| Gross Profit | US$84.85m |
| Other Expenses | US$140.13m |
| Earnings | -US$55.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.10 |
| Gross Margin | 34.02% |
| Net Profit Margin | -22.17% |
| Debt/Equity Ratio | 13.0% |
How did IMCR perform over the long term?
See historical performance and comparison